Junko Tanizaki

3.7k total citations · 1 hit paper
69 papers, 2.3k citations indexed

About

Junko Tanizaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Junko Tanizaki has authored 69 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 44 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in Junko Tanizaki's work include Lung Cancer Treatments and Mutations (41 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Junko Tanizaki is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Junko Tanizaki collaborates with scholars based in Japan, United States and China. Junko Tanizaki's co-authors include Kazuhiko Nakagawa, Isamu Okamoto, Hidetoshi Hayashi, Kazuto Nishio, Kazuko Sakai, Koji Haratani, Kaoru Tanaka, Masayuki Takeda, Akihiko Ito and Hisato Kawakami and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Junko Tanizaki

66 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Junko Tanizaki Japan	24	1.7k	1.3k	680	287	283	69	2.3k
Liza C. Villaruz United States	23	1.3k 0.8×	1.2k 0.9×	675 1.0×	422 1.5×	228 0.8×	81	2.0k
Amrita Desai United States	19	1.3k 0.8×	1.1k 0.8×	657 1.0×	359 1.3×	133 0.5×	36	2.3k
Lorenza Landi Italy	22	1.1k 0.7×	1.0k 0.7×	611 0.9×	423 1.5×	154 0.5×	85	1.8k
Zhong‐Yi Dong China	23	2.0k 1.2×	1.5k 1.1×	853 1.3×	722 2.5×	532 1.9×	73	3.0k
Yasutoshi Kuboki Japan	27	2.1k 1.2×	1.2k 0.9×	556 0.8×	309 1.1×	298 1.1×	143	2.8k
Soji Kakiuchi Japan	21	850 0.5×	910 0.7×	998 1.5×	313 1.1×	153 0.5×	41	1.9k
Petros Nikolinakos United States	20	1.5k 0.9×	986 0.7×	628 0.9×	869 3.0×	404 1.4×	51	2.4k
Iacopo Petrini Italy	27	1.0k 0.6×	723 0.5×	884 1.3×	688 2.4×	193 0.7×	91	2.5k
Jinming Yu China	19	1.2k 0.7×	671 0.5×	579 0.9×	456 1.6×	501 1.8×	66	2.3k
Shelley Coleman United States	7	2.8k 1.6×	1.9k 1.4×	399 0.6×	387 1.3×	599 2.1×	10	3.2k

Countries citing papers authored by Junko Tanizaki

Since Specialization

Citations

This map shows the geographic impact of Junko Tanizaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Junko Tanizaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Junko Tanizaki more than expected).

Fields of papers citing papers by Junko Tanizaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Junko Tanizaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Junko Tanizaki. The network helps show where Junko Tanizaki may publish in the future.

Co-authorship network of co-authors of Junko Tanizaki

This figure shows the co-authorship network connecting the top 25 collaborators of Junko Tanizaki. A scholar is included among the top collaborators of Junko Tanizaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Junko Tanizaki. Junko Tanizaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shiraishi, N., Takayuki Takahama, Kazuko Sakai, et al.. (2025). Detection of Overlooked Rare EGFR Mutations in Non‐small Cell Lung Cancer Using Multigene Testing. Thoracic Cancer. 16(3). e70007–e70007. 1 indexed citations

Wu, Yi‐Long, et al.. (2025). 124TiP: TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. Journal of Thoracic Oncology. 20(3). S87–S88. 1 indexed citations

Ohta, Ryuichi, et al.. (2025). Paraneoplastic Syndromes Mimicking Dermatomyositis and Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome in Cancer of Unknown Primary Origin: A Case Report. Cureus. 17(3). e81376–e81376.

Lü, Shun, Jonathan W. Goldman, Junko Tanizaki, et al.. (2024). A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).. Journal of Clinical Oncology. 42(16_suppl). TPS8656–TPS8656. 4 indexed citations

Tanizaki, Junko, Koji Matsumoto, Toshiki Masuishi, et al.. (2024). Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).. Journal of Clinical Oncology. 42(16_suppl). 3025–3025. 2 indexed citations

Hagiwara, Satoru, Junko Tanizaki, Hidetoshi Hayashi, et al.. (2024). Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. Cancer Reports. 7(2). e1960–e1960. 1 indexed citations

Fujita, Yoshihiko, Hiromichi Matsuoka, Yasutaka Chiba, et al.. (2024). Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain. Molecular and Clinical Oncology. 22(2). 14–14. 1 indexed citations

Tanizaki, Junko, H. Akamatsu, Jian Su, et al.. (2023). 600TiP Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC). Annals of Oncology. 34. S1705–S1706.

Suzuki, Shinichiro, Kimio Yonesaka, Takeshi Teramura, et al.. (2021). KRAS Inhibitor Resistance in MET -Amplified KRAS G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms. Clinical Cancer Research. 27(20). 5697–5707. 66 indexed citations

10.

Hayashi, Hidetoshi, Shunichi Sugawara, Yasushi Fukuda, et al.. (2021). A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR -Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). Clinical Cancer Research. 28(5). 893–902. 49 indexed citations

11.

Haratani, Koji, Hidetoshi Hayashi, Shigeki Shimizu, et al.. (2020). Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(8). 2037–2046. 172 indexed citations

12.

Jang, Jaebong, Jieun Son, Eunyoung Park, et al.. (2018). Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angewandte Chemie International Edition. 57(36). 11629–11633. 23 indexed citations

13.

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

14.

Tanizaki, Junko, Dalia Ercan, Marzia Capelletti, et al.. (2015). Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research. 75(15). 3139–3146. 30 indexed citations

15.

Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →

16.

Tsurutani, Junji, Katsumasa Kuroi, Tsutomu Iwasa, et al.. (2015). Phase I study of weekly nab‐paclitaxel combined with S‐1 in patients with human epidermal growth factor receptor type 2‐negative metastatic breast cancer. Cancer Science. 106(6). 734–739. 9 indexed citations

17.

Matsuoka, Hiromichi, Junji Tsurutani, Junko Tanizaki, et al.. (2013). Regression of brain metastases from breast cancer with eribulin: a case report. BMC Research Notes. 6(1). 541–541. 18 indexed citations

18.

Tanizaki, Junko, Isamu Okamoto, Takafumi Okabe, et al.. (2012). Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(22). 6219–6226. 126 indexed citations

19.

Tanizaki, Junko, Isamu Okamoto, Kazuko Sakai, & Kazuhiko Nakagawa. (2011). Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. British Journal of Cancer. 105(6). 807–813. 99 indexed citations

20.

Takezawa, Ken, Isamu Okamoto, Junko Tanizaki, et al.. (2010). Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor. Molecular Cancer Therapeutics. 9(6). 1647–1656. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact